Press Release

Cerenome Launches CNSide® CSF Molecular Profile Tests

New DNA and RNA tests expand CNSide beyond leptomeningeal metastases to molecular profiling across CNS oncology HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company ”), today announced the…